Kornimate/medical-research-clean huggingface dataset:
non-interventional study of xeloda (capecitabine) in patients with gastric cancer

Conditions: Gastric Cancer

Summary: this observational study will collect prospective data on the safety and tolerability of xeloda in patients with advanced gastric cancer from every day clinical practice. documentation of treatment for each patient is to continue until the end of treatment per oncologist's assessment.


Eligibility criteria:
inclusion criteria: * patients aged \>/=18 years, with metastatic gastric cancer who are available for prospective documentation of their treatment (first-line chemotherapy) * informed consent exclusion criteria: * contraindications to xeloda per the summary of product characteristics (smpc)
effect of spinal stabilization exercises on epicardial fat tissue and exercise capacity in hypertensives

Conditions: Hypertension

Summary: it has been suggested that epicardial adipose tissue (eat) may be an adjunctive marker to classical risk factors for the presence and severity of coronary artery disease. eat thickness is also associated with mets and hypertension, high levels of low-density lipoprotein cholesterol and insulin resistance.studies have shown that moderate-intensity and high-intensity aerobic exercise and resistance exercise training reduce eat. however, aerobic and resistance exercises may be found challenging and demanding by individuals and in most cases, high or moderate intensity exercise may be considered difficult. in a study conducted in physically inactive individuals, it was concluded that there was a significant increase in heart rate and bp following spinal stabilisation exercises performed 4 days a week for a total of 8 sessions for 2 weeks, but the increase in these cardiac parameters would tend to decrease following regular exercise. in the current literature, there is no study evaluating the effect of spinal stabilisation exercise on eat thickness, exercise capacity and cardiovascular parameters in individuals with ht. barriers to access to healthcare services such as distance, time and cost can be overcome with technology. covid-19 has accelerated the transition of many physiotherapy services to telerehabilitation. evidence has shown that telerehabilitation is an effective delivery model for providing face-to-face physiotherapy services with equal or even superior outcomes, especially in musculoskeletal treatment. the aim of this study was to determine the effect of spinal stabilisation exercise with telerehabilitation on eat and exercise capacity in individuals with ht.


Eligibility criteria:
inclusion criteria: 1. being followed up with hypertension for at least 6 months 2. volunteering to participate in the study 3. speaking turkish 4. being literate 5. not having participated in any structured exercise programme for at least 6 months exclusion criteria: 1. severe valvular disease 2. having heart failure 3. having cardiomyopathy 4. myocardial infarction at least 6 months ago 5. stable or unstable angina pectoris 6. left ventricular ejection fraction below 40 7. presence of peripheral artery disease 8. history of deep vein thrombosis, pulmonary embolism or stroke in the past 9. chronic kidney disease 10. having thyroid diseases 11. active infectious or inflammatory disease 12. body mass index \>40 kg/m2 13. having a serious psychiatric illness such as panic disorder or major depression

Keywords: epicardial adipose tissue hypertension exercises capacity telerehabilitation spinal stabilisation exercise
effects of metabolic testing data and education on attitudes and beliefs related to carbohydrate intake in adolescent female athletes

Conditions: Nutritional Deficiency

Summary: many studies have consistently shown that females across sports under consume carbohydrate. registered dietitians working with athletes have also reported female athletes chronically under consume carbohydrate. the primary objective of this study is to compare the effectiveness of education versus education plus interpreted individual metabolic (exercise) testing results to change attitudes and beliefs of female athletes regarding carbohydrate intake. the secondary objective is to assess the effectiveness of the education alone on attitudes and beliefs towards consuming carbohydrate in female athletes. the study hypothesis is that education alone will not significantly impact attitudes and beliefs, and that metabolic testing and the interpretation of the individual results will alter attitudes and beliefs toward carbohydrate intake.


Eligibility criteria:
inclusion criteria: 1. females aged between the ages of 13-19 years old 2. non-smoker 3. currently enrolled in an img academy sport 4. willing to fast overnight (10 hours) prior to testing (for metabolic testing group). 5. understand the protocol and be able to give verbal and written informed consent for participation as well as obtain parental consent if \<18 years of age. 6. must be fluent in english reading, writing, and speaking. 7. you are not employed by, or have a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any gatorade product. if you are unsure if a company would be considered a competitor to gatorade, let the study investigator know the name of the other company and the nature of your relationship to that company before you sign the informed consent 8. if subject has asthma, they may still participate in but will be required to bring their prescribed inhaler if placed in the metabolic testing group exclusion criteria: 1. expulsion from school for any reason 2. leaving the img sports team 3. pregnant or planning to become pregnant 4. participated in any other clinical trial in the past 30 day 5. participated in any pepsico trial in the past 6 months 6. physical injury that would prevent participation in exercise group

Keywords: exercise performance metabolic testing education carbohydrate adolescent female athlete
a prospective, multi centre, interventional, non-comparator, open label study to demonstrate the efficacy, performance and safety of convafoam™ silicone, convafoam™ border and convafoam™ non-adhesive dressings in the management of surgical and traumatic wounds

Conditions: Surgical Wound; Trauma-related Wound

Summary: a prospective, multi centre, interventional, non-comparator, open label study to demonstrate the efficacy, performance and safety of convafoam™ silicone, convafoam™ border and convafoam™ non-adhesive dressings in the management of surgical and traumatic wounds

a prospective, multi centre, interventional, non-comparator, open label study to demonstrate the efficacy, performance and safety of convafoam™ silicone, convafoam™ border and convafoam™ non-adhesive dressings in the management of surgical and traumatic wounds for up to 4 weeks

Eligibility criteria:
inclusion criteria: * patients aged 18 years and over * patients able and willing to provide informed consent * patients with surgical wounds including incisional wounds including laparoscopic * wounds and surgical wounds healing by secondary intention. * patients with traumatic wounds * patients must be willing to attend visits as per schedule in protocol exclusion criteria: * patients with known allergies to any of the materials used in the dressing * patients who require any oxidising agents such as hydrogen peroxide or hypochlorite solutions. * patients, who in the opinion of the investigator, is considered unsuitable for any other reason * patients with wounds showing signs of infection on presentation or not resolving with the use of antibiotics
gnrha for luteal phase support in long gnrha protocol cycles

Conditions: Infertility

Summary: evaluation of the effect of adding a single dose of gonadotropin releasing hormone agonist (gnrha) as a luteal phase support on the outcomes of intracytoplasmic sperm injection (icsi) following long gnrha protocol

endometrial preparation for embryo transfer (et) will be started after oocyte retrieval by giving 800 mg/day natural progesterone vaginal supplement + 4 mg/day estradiol oral supplement. the patients will be randomly divided into 2 groups for luteal phase support: (i) group a (gnrha group) in which the luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (et) with subcutaneous administration of a single dose (0.2 mg) of gnrha (triptorelin) 6 days after oocyte retrieval, and (ii) group b (control group) in which the luteal phase support will be continued only by the same regimen started on the day of oocytes retrieval until 2 weeks after et

Eligibility criteria:
inclusion criteria: * women subjected to icsi through controlled ovarian hyperstimulation (coh) with pituitary downregulation by gnrha. exclusion criteria: * moderate or severe endometriosis. * hydrosalpinx. * uterine abnormalities. * myoma. * previous uterine surgery.

Keywords: luteal phase support, icsi, gnrha
aromatherapy massage in migraine attacks

Conditions: Pain; Head Pain; Quality of Life

Summary: the aim of the study was to determine the effect of aromatherapy massage on the pain severity and quality of life in patients diagnosed with migraine in addition to medical treatment during an acute migraine attack. in addition to medical treatments, complementary and supportive therapies are commonly used to cope with pain during a migraine attack. in recent years, aromatherapy through massage has become more common to reduce the severity of pain, make the patient painless and improve the quality of life. aromatherapy applications are the application of pain relief oil mixtures through massage. lavender and peppermint essential oils are mostly used in aromatherapy applications to reduce pain. therefore, a mixture of mint and lavender oil was used in the study.

the study was planned and conducted as a randomized controlled experiment. the sample of the randomized controlled trial consisted of 70 patients who applied to the emergency department with a migraine attack and met the study criteria. data were collected via patient information form, 24-hour migraine quality of life scale, visual analogue scale, sphygmomanometer, and pulse oximeter. along with the medical treatment, patients of experimental group were massaged for 15 minutes with an aromatic oil mixture (lavender and peppermint) applied on the temple and root of the neck, and this application continued for three weeks. control group patients, however, received only medical treatment. descriptive statistics methods, shapiro wilks test, wilcoxon signed ranks test, mann whitney u test, kruskal wallis test, fisher's exact test and chi-square test were used for data evaluation.

Eligibility criteria:
inclusion criteria: diagnosed with migraine according to international headache society 2013 being able to speak turkish, being between the ages of 18 and 50, being literate, not having any communication problems, agreeing to participate in the study, having vital signs within normal limits not being diagnosed with a psychiatric disorder exclusion criteria: having a headache other than migraine being the ages under the 18 having any communication problems, having vital signs above or under normal limits being diagnosed with a psychiatric disorder

Keywords: aromatherapy massage
study of oral metronidazole on postoperative chemotherapy in colorectal cancer

Conditions: Colorectal Cancer Stage II; Colorectal Cancer Stage III

Summary: fusobacterium nucleatum (fusobacterium nucleatum, fn) has been identified as an independent risk factor for recurrence of colorectal cancer. in this study, oral metronidazole would be used to reduce the abundance of fn in patients with high fn, so as to explore whether oral metronidazole can improve the efficacy of postoperative chemotherapy in patients with colorectal cancer.

gut microbiota are linked to chronic inflammation and carcinogenesis. chemotherapy failure is the major cause of recurrence and poor prognosis in colorectal cancer patients. previously in the investigators' research, the investigators find the contribution of gut microbiota to chemoresistance in patients with colorectal cancer. the investigators found that fusobacterium nucleatum (fn) was abundant in colorectal cancer tissues in patients with recurrence post chemotherapy, and was associated with patient clinicopathological characterisitcs. furthermore, the investigators' bioinformatic and functional studies demonstrated that fn promoted colorectal cancer resistance to chemotherapy. metronidazole has been known to treat with anaerobe infection, including fusobacterium. so oral metronidazole would be used to reduce the abundance of fn in patients with high fn, so as to explore whether oral metronidazole can improve the efficacy of postoperative chemotherapy in patients with colorectal cancer.

Eligibility criteria:
inclusion criteria: * individuals aged 18-75 years * individuals firstly confirmed by surgery pathology as colorectal cancer (ajcc cancer staging ii - iii), who need mfolfox6 or capeox postoperative chemotherapy * individuals with fn - deltact value in colon tissue samples detected by qpcr ≥-12 before receiving chemotherapy * individuals who could tolerate chemotherapy drugs: ecog (eastern cooperative oncology group) score ≤2 points, wbc(white blood cell) ≥4.0×10\^9/l, hb （hemoglobin） ≥80g/l, plt （platelet） ≥80×10\^9/l, alt （alanine aminotransferase）\< 2uln （upper limmit of normal）, scr （creatinine）\< 1.5uln * individuals who participate this study and sign the informed consent form willingly. exclusion criteria: * individuals with colorectal adenoma or non-colorectal cancer, such as inflammatory bowel disease * individuals with a history of familial adenomatous polyposis (fap) * individuals with severe heart, lung, brain, kidney, gastrointestinal or systemic diseases * individuals who used antibiotics for more than 5 days in 1 month prior to chemotherapy * individuals with stage i or iv colorectal cancer, or with stage ii colorectal cancer who do not need postoperative chemotherapy * individuals with contraindications for metronidazole * individuals who unwilling to participate this study，or unwilling to sign the informed consent form * individuals with any conditions that the researchers considered inappropriate for inclusion

Keywords: metronidazole gut microbiota postoperative chemotherapy colorectal cancer fusobacterium nucleatum
the effect of high dose simvastatine on multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of the study is to evaluate the effect of high doses of simvastatine on bone metabolisme and biochemical markers of disease in multiple myeloma


Eligibility criteria:
inclusion criteria: * multiple myeloma-patients in need of treatment * stable og progressive disease * age = or \> 18 years * performance status \< 3 * life expectancy \> 3 months exclusion criteria: * pregnancy * patients incapable of giving personally concent * renal insufficiens with creatinine clearance below 25 ml/min * alanin aminotransferasis \> 2,5 x upper reference limit * thyroxine below lower reference limit * known familiar muscle-disease ar previous myopati * creatinine kinase \> 10 x upper reference limit * medication with drugs with known interactions wiht simvastatine

Keywords: multiple myeloma statins bone
metformin treatment in infants after perinatal brain injury

Conditions: Hypoxic Ischemic Encephalopathy of Newborn; Premature Birth

Summary: a phase i study to test the feasibility and safety of treatment with metformin in infants affected by hypoxic ischemic encephalopathy (hie) or prematurity-related brain injury


Eligibility criteria:
inclusion criteria: hie patients: 1. \> 35 weeks gestation at time of birth 2. ≤3 months at time of consent 3. clinical diagnosis of hie 4. infant received therapeutic hypothermia for the treatment of hie 5. family lives within one hour distance of the hospital for sick children (in order to facilitate home visits) preterm infants: 1. \<32 weeks gestation at time of birth 2. 36-44 weeks corrected (postmenstrual) gestational age at time of metformin administration 3. clinical team anticipates hospitalization at sickkids for at least 1 week after study enrollment exclusion criteria: 1. have a known genetic or chromosomal disorder. 2. congenital or acquired liver or kidney disease that might, in the opinion of the principal investigator or delegate, affect drug metabolism. 3. history of hypoglycemia in the newborn period requiring glucose infusion rate \> 10 mg/kg/min or treatment with glucagon or diazoxide. 4. any condition or diagnosis, that could in the opinion of the principal investigator or delegate, interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk 5. \>3 months of age at the time of enrollment (term hie patients only) 6. weight \<10%ile based on who growth charts at time of initiation of study drug (term hie patients only). 7. maternal use of metformin while actively breastfeeding.

Keywords: hypoxic ischemic encephalopathy newborn metformin prematurity
efficacy and safety study of vb-1953 topical gel for inflammatory facial acne vulgaris

Conditions: Acne Vulgaris

Summary: a phase 2, multicenter, randomized, double-blind, vehicle controlled, dose-ranging study in the treatment of acne vulgaris,

this will be a phase 2, multicenter, randomized, double-blinded, dose-ranging, parallel arm comparison study in male and non-pregnant female subjects, 9 through 45 years of age (inclusive) with facial acne vulgaris. this dose-ranging study, intended to identify the dose(s), will consist of 7 study visits over 14 weeks:

Eligibility criteria:
inclusion criteria: * males or non-pregnant females 9 to 45 years of age (inclusive) at the time of consent/assent. * have a clinical diagnosis of moderate to severe (grade 3 or 4) facial acne vulgaris, as determined by the investigator's global assessment (iga). * have 20 to 50 inflammatory lesions (papules, pustules) on the face. * have 20 to 60 non-inflammatory lesions on the face. exclusion criteria: * has more than two (2) facial nodulocystic lesions. * female subject is pregnant, lactating, or is planning to become pregnant during the study. * has active nodulocystic acne or acne conglobata, acne fulminans, or other forms of acne (e.g., acne mechanica). in the opinion of the investigator, the subject has a skin pathology or other medical condition that is clinically significant (e.g., obesity) and will preclude participation in the study. * has presence of any skin condition on the face (e.g., rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acnetiform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis) in the opinion of the investigator that could interfere with the diagnosis or assessment of acne vulgaris or evaluation of the investigational product (ip) or requires the use of interfering topical or systemic therapy. * not willing to minimize or avoid natural and artificial sunlight exposure during treatment.
medications for chronic hiv: education and collaboration

Conditions: HIV Infections; Acquired Immunodeficiency Syndrome; Medication Adherence

Summary: this study will examine whether a computerized, self-administered assessment of patient medication adherence and health behaviors, plus support for adherence, improves the ability of clinicians to identify adherence problems and leads to better adherence.

antiretroviral medications are highly effective in controlling hiv, if patients adhere to the regimen. however, hiv medication adherence problems are very common, and evidence is clear that providers have great difficulty 'diagnosing' poor adherence accurately. if healthcare providers can identify patients with adherence problems, they can intervene to help patients overcome these problems and take their medications as prescribed, which can improve symptoms and quality and length of life. both clinicians and hiv positive patients will be recruited to this study. before each clinic visit, patients randomized to the intervention will be asked to answer questions about their medications, medication-taking behavior, and risk-factors for non-adherence on medchec, a tablet touch-screen computer that generates provider and patient reports. we will give these reports to the provider and patient to assist with the clinical visit. based on the medchec-generated report, the patient may be referred to an adherence care manager (acm). the acm will assist the patient in overcoming adherence barriers by telephone and in-clinic counseling. the study will evaluate the effects of this system on adherence and clinical care using both quantitative methods (randomized controlled trials of effects on adherence and providers' adherence estimates), and qualitative methods.

Eligibility criteria:
inclusion criteria: * over 18 years of age * confirmed hiv-positive * on or newly starting antiretroviral medication for hiv * under treatment at one of the study sites * available by telephone exclusion criteria: * clinically diagnosed by provider with significant cognitive impairment, or mini-mental status exam score less than or equal to 22 * inability to read english * inability or refusal to use medchec touch-screen computer * inability or refusal to use any form of electronic drug monitoring device (mems) * never available by telephone

Keywords: hiv aids adherence antiretroviral acasi haart complementary therapies adherence care manager
potential effect for the smoking on periodontitis from the perspective of arginine metabolites

Conditions: Periodontitis; Smoking; Inflammatory Response

Summary: arginine metabolites are amino acids that are associated with vascular tone regulation and the level of inflammation, with critical roles in the synthesis of no. our aim was to determine the adma, sdma, l-nmma, l-arginine, l-homoarginine and il-6 levels in saliva and serum samples from periodontitis patients and periodontally healthy individuals and to assess the levels of these compounds according to smoking status and compare these levels to those of healthy individuals.

the study consisted of four groups: healthy individuals (control (c); n=20), smokers with healthy periodontium (s-c; n=20), nonsmokers with stage iii grade b generalized periodontitis (p; n=20) and smokers with stage iii grade c generalized periodontitis (s-p; n=18). clinical periodontal parameters were measured. the determination of methylated arginine metabolites was carried out by lc-ms/ms.

Eligibility criteria:
inclusion criteria: * systemically healthy * clinical diagnosis of periodontitis * clinical diagnosis of periodontal health * for smoking group the so kerr were denied as smoking at least 10 cigarettes per day and the duration should more than 10 years. exclusion criteria: * history of regular use of systemic antibiotics anti-inflammatory, or antioxidant drugs (previous 3 months) * nonsurgical periodontal treatment (previous 6 months) * surgical periodontal treatment (previous 12 months) * presence of\<10 teeth * current medications affecting gingival health (calcium channel blockers, phenytoin, cyclosporine, and hormone replacement therapy) * diabetes * diagnosis of rheumatoid arthritis * pregnancy * lactating * excessive alcohol consumption.

Keywords: periodontitis, arginine metabolites, smoking